The Relative Strength (RS) Rating for Masimo entered a new percentile Wednesday, with a rise from 78 to 81.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique rating tracks share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best stocks tend to have an 80 or better RS Rating as they launch their biggest runs.
Masimo is working on a consolidation with a 194.88 buy point. See if it can clear the breakout price in volume at least 40% higher than normal.
Regarding top and bottom line numbers, Masimo has posted rising EPS growth in each of the last four reports. Top line growth has also moved higher over the same time frame.
Masimo holds the No. 3 rank among its peers in the Medical-Systems/Equipment industry group. iRadimed is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
